NBY (NovaBay Pharmaceuticals) 3-Year EBITDA Growth Rate : 43.30% (As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is NovaBay Pharmaceuticals 3-Year EBITDA Growth Rate?

NovaBay Pharmaceuticals's EBITDA per Share for the three months ended in Sep. 2024 was $-0.26.

During the past 3 years, the average EBITDA Per Share Growth Rate was 43.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 37.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 42.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of NovaBay Pharmaceuticals was 62.70% per year. The lowest was -54.80% per year. And the median was 26.60% per year.

Competitive Comparison of NovaBay Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, NovaBay Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovaBay Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NovaBay Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where NovaBay Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.

NovaBay Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

NovaBay Pharmaceuticals (AMEX:NBY) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

NovaBay Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

NovaBay Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NovaBay Pharmaceuticals Inc (AMEX:NBY) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

2000 Powell Street, Suite 1150, Emeryville, CA, USA, 94608

Website

https://www.novabay.com

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.

Executives

Tommy Law	officer: Interim CFO	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Jeffrey Kunin	officer: President, DERMAdoctor, LLC	4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Audrey Kunin	officer: Chief Product Officer	4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Justin Hall	officer: General Counsel	5980 HORTON STREET, SUITE 550, EMERYVILLE CA 94608
Yongxiang Zheng	director	NO.10, UNIT 1, LIJING VILLA, TIANZHU, SHUNYI DISTRICT, BEIJING F4 101316
Julie Garlikov	director	2420 17TH STREET, SUITE 220, DENVER CO 80202
Andrew D. Jones	officer: CFO and Treasurer	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Mijia Wu	director	SUITE 6C, BLDG 3, YOU YOU CENTURY PLAZA, NO 428 YANG GAO SOUTH ROAD, SHANGHAI F4 CHINA
Jian Ping Fu	10 percent owner	LEVEL 1, BLDG 1, GREENWOOD BUSINESS PARK, 301 BURWOOD HWY, BURWOOD C3 3125
Swan Sit	director	95 JACKSON STREET, NEWTON MA 02459
Yenyou Zheng	director	1055 WEST HASTINGS STREET, SUITE 1980, VANCOUVER A1 V6E 2E9
Xiaopei Wang	director	2/44 FRANKLIN ROAD, DONCASTER EAST C3 3109
Jason Philip Raleigh	officer: Interim CFO and Treasurer	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Pioneer Pharma (hong Kong) Co Ltd	10 percent owner	FLAT 2605, 26/F TRENDY CENTRE, 682 CASTLE PEAK ROAD, KOWLOON K3 000000
Yanbin Liu	director	27/F TWO EXCHANGE SQUARE, 8 CONNAUGHT PLACE, CENTRAL K3 00000